Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $2.81 Million - $3.37 Million
8,200 New
8,200 $3.34 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $15.7 Million - $17.7 Million
55,000 New
55,000 $15.9 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $1.33 Million - $1.68 Million
7,500 New
7,500 $1.65 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $6.32 Million - $7.45 Million
-33,700 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $6.98 Million - $8.13 Million
33,700 New
33,700 $7.24 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $123B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.